Verastem (VSTM) has been in focus after a busy stretch that combined fresh clinical milestones, a new FDA filing and a sizeable capital raise, all against a still loss-making earnings backdrop.
Verastem’s story has been playing out in the share price too, with a sharp 10.34% 1 day share price drop and a 13.74% 7 day share price decline arriving after its earnings miss, capital raises and fresh FDA progress. This comes even though the 90 day share price return of 24.78% and 3 year total shareholder return of 31.82% still point to momentum building off a much weaker 5 year total shareholder return of 77.68%.
Scan how Verastem’s setup compares to other oncology names facing similar trial and funding catalysts by running through the curated 19 high quality undiscovered gems in the same space.
After a sharp pullback despite fresh cash, an accepted NDA and a defined Phase 3 path, Verastem now forces a simple question: Does the current valuation still compensate you for the clinical and financing risk?
Most Popular Narrative: 51% Undervalued
Verastem’s most followed valuation story pegs fair value at about $17.22 a share, well above the last close of $8.41, which puts the recent selloff in a very different light.
The combination of an active commercial franchise and a RAS or MAPK focused pipeline, underpinned by a cash position of US$137.7 million and a stated runway into the second half of 2026, gives Verastem room to fund launch activities and clinical development, which directly touches future earnings and the potential to narrow current net losses.
See why 4 investors see Verastem as 51% undervalued.
Result: Fair Value of $17.22 (UNDERVALUED)
Still, Verastem’s loss making profile and limited cash runway into the second half of 2026 leave the story heavily exposed to trial outcomes and future funding needs.
Find out about the key risks to this Verastem narrative.
Next Steps
Mixed signals around Verastem do not have to leave you on the fence. Act while the facts are fresh and weigh both sides for yourself by reviewing the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Verastem?
If Verastem has your attention, do not stop with just one ticker. Use focused screens to surface other opportunities that match your risk, income and quality preferences.
- Target potential mispricings by reviewing a curated set of quality shares that still look underappreciated through the 39 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by filtering for companies with resilient finances using the 29 resilient stocks with low risk scores.
- Hunt for lesser known opportunities with solid fundamentals before the crowd catches on by scanning the 19 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com